Tobira Therapeutics Company Profile (NASDAQ:TBRA)

About Tobira Therapeutics (NASDAQ:TBRA)

Tobira Therapeutics logoTobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Industry, Sector and Symbol: Average Prices:
  • 50 Day Moving Avg: $35.35
  • 200 Day Moving Avg: $15.25
  • 52 Week Range: $3.76 - $42.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.31
  • P/E Growth: 0.00
  • Return on Equity: -109.45%
  • Return on Assets: -71.32%
  • Debt-to-Equity Ratio: 0.44%
  • Current Ratio: 5.38%
  • Quick Ratio: 5.38%
  • Average Volume: 583,983 shs.
  • Beta: -2.38

Frequently Asked Questions for Tobira Therapeutics (NASDAQ:TBRA)

What is Tobira Therapeutics' stock symbol?

Tobira Therapeutics trades on the NASDAQ under the ticker symbol "TBRA."

How were Tobira Therapeutics' earnings last quarter?

Tobira Therapeutics Inc (NASDAQ:TBRA) posted its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.08. The company had revenue of $1.06 million for the quarter, compared to analysts' expectations of $0.15 million. View Tobira Therapeutics' Earnings History.

Where is Tobira Therapeutics' stock going? Where will Tobira Therapeutics' stock price be in 2017?

5 brokerages have issued 12 month price targets for Tobira Therapeutics' shares. Their predictions range from $11.00 to $305.00. On average, they expect Tobira Therapeutics' share price to reach $86.80 in the next year. View Analyst Ratings for Tobira Therapeutics.

What are analysts saying about Tobira Therapeutics stock?

Here are some recent quotes from research analysts about Tobira Therapeutics stock:

  • 1. According to Zacks Investment Research, "Tobira Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to treat liver disease, inflammation, liver fibrosis and human immunodeficiency virus. Tobira Therapeutics, Inc., formerly known as Regado Biosciences, Inc., is headquartered in San Francisco, CA. " (10/20/2016)
  • 2. Cowen and Company analysts commented, "TBRA’s CVC Ph2 CENTAUR trial recently missed the primary endpoint (NAS reduction)." (8/10/2016)

Who are some of Tobira Therapeutics' key competitors?

How do I buy Tobira Therapeutics stock?

Shares of Tobira Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Tobira Therapeutics stock cost?

One share of Tobira Therapeutics stock can currently be purchased for approximately $42.09.

Analyst Ratings

Consensus Ratings for Tobira Therapeutics (NASDAQ:TBRA) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $86.80 (106.22% upside)

Analysts' Ratings History for Tobira Therapeutics (NASDAQ:TBRA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/22/2016Leerink SwannReiterated RatingOutperform$15.00 -> $45.00N/AView Rating Details
9/22/2016MizuhoReiterated RatingBuy$305.00N/AView Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> Hold$19.00 -> $42.00N/AView Rating Details
8/13/2016HC WainwrightReiterated RatingBuy$22.00 -> $31.00N/AView Rating Details
8/10/2016Cowen and CompanyReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Tobira Therapeutics (NASDAQ:TBRA)
Earnings by Quarter for Tobira Therapeutics (NASDAQ:TBRA)
Earnings History by Quarter for Tobira Therapeutics (NASDAQ:TBRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.63)($0.71)$0.15 million$1.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.53)($0.65)$0.11 millionViewN/AView Earnings Details
3/3/2016Q415($0.52)($0.50)ViewN/AView Earnings Details
11/10/2015Q315($1.00)($1.22)ViewListenView Earnings Details
8/11/2015Q215($0.99)ViewListenView Earnings Details
11/6/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/11/2014Q214($0.51)($0.63)ViewN/AView Earnings Details
5/14/2014Q114($0.62)($1.30)ViewN/AView Earnings Details
11/7/2013($0.43)($1.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Tobira Therapeutics (NASDAQ:TBRA)
Current Year EPS Consensus Estimate: $-2.60 EPS
Next Year EPS Consensus Estimate: $-2.18 EPS


Dividend History for Tobira Therapeutics (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Tobira Therapeutics (NASDAQ:TBRA)
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 62.42%
Insider Trades by Quarter for Tobira Therapeutics (NASDAQ:TBRA)
Institutional Ownership by Quarter for Tobira Therapeutics (NASDAQ:TBRA)
Insider Trades by Quarter for Tobira Therapeutics (NASDAQ:TBRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/31/2016Pentwater Capital Management LMajor ShareholderBuy15,000$41.84$627,600.00View SEC Filing  
10/18/2016Pentwater Capital Management LMajor ShareholderBuy40,000$40.06$1,602,400.00View SEC Filing  
10/17/2016Pentwater Capital Management LMajor ShareholderBuy31,700$40.07$1,270,219.00View SEC Filing  
10/4/2016Pentwater Capital Management LMajor ShareholderBuy4,481$39.83$178,478.23View SEC Filing  
9/29/2016Pentwater Capital Management LMajor ShareholderBuy15,519$39.49$612,845.31View SEC Filing  
9/26/2016Pentwater Capital Management LMajor ShareholderBuy50,000$39.00$1,950,000.00View SEC Filing  
9/23/2016Pentwater Capital Management LMajor ShareholderBuy100,000$39.19$3,919,000.00View SEC Filing  
9/22/2016Pentwater Capital Management LMajor ShareholderBuy1,624,200$39.04$63,408,768.00View SEC Filing  
7/13/2016A/S NovoMajor ShareholderSell59,067$12.02$709,985.34View SEC Filing  
7/7/2016A/S NovoMajor ShareholderSell92,119$12.20$1,123,851.80View SEC Filing  
6/30/2016A/S NovoMajor ShareholderSell66,814$13.04$871,254.56View SEC Filing  
6/6/2016A/S NovoMajor ShareholderSell187,500$10.37$1,944,375.00View SEC Filing  
3/4/2016A/S NovoMajor ShareholderSell190,000$6.80$1,292,000.00View SEC Filing  
11/18/2015A/S Novomajor shareholderSell225,000$9.79$2,202,750.00View SEC Filing  
5/4/2015A/S NovoMajor ShareholderBuy838,041$10.62$8,899,995.42View SEC Filing  
5/4/2015Parters Vii L P DomainMajor ShareholderBuy277,777$10.62$2,949,991.74View SEC Filing  
4/16/2014Robert Kierlinmajor shareholderBuy575,000$6.00$3,450,000.00View SEC Filing  
2/5/2014Robert Kierlinmajor shareholderBuy400,000$5.00$2,000,000.00View SEC Filing  
8/27/2013Raphael WisniewskiDirectorBuy1,215,708$4.00$4,862,832.00View SEC Filing  
8/27/2013Rmi Investments S.A.R.L.Major ShareholderBuy3,866,529$4.00$15,466,116.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Tobira Therapeutics (NASDAQ:TBRA)
Latest Headlines for Tobira Therapeutics (NASDAQ:TBRA)
DateHeadline logoThe Lesson in Straight Path's Short Squeeze - May 11 at 11:06 PM logoBiotech Forum Daily Digest: Upward Resistance Levels Continue To Hold; Spotlight On Foamix Pharmaceuticals - March 4 at 1:11 AM logoAllergan Hints It Is Ready to Make a Splash for More Near-term Growth - January 11 at 5:38 AM logoBlog Coverage Allergan Completes the $1.69 Billion Acquisition of NASH Therapy Maker - November 2 at 11:26 AM logoBiotech Stocks on Investors' Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical - PR Newswire (press release) - November 1 at 12:21 PM logoTOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisiti - November 1 at 12:21 PM logoNotable Thursday Option Activity: TBRA, CRUS, BCOR - Nasdaq - October 28 at 11:39 AM logoNotable Thursday Option Activity: TBRA, CRUS, BCOR - October 27 at 7:46 PM logoAllergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman - October 26 at 7:37 PM logoAllergan's Nocturia Drug Gets FDA Advisory Committee's Nod - October 21 at 11:13 AM logoTobira Therapeutics (TBRA) Presents Phase 2b CENTAUR Year 1 Analysis at AASLD Annual Meeting - October 20 at 7:55 PM logoTobira Therapeutics Announces Late-Breaking Oral... - October 20 at 12:45 PM logoTobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting - October 20 at 12:45 PM logo10:48 am Tobira Therapeutics announces a late-breaking oral presentation of Centaur Phase 2b trial results will be presented at the American Academy for the Study of Liver Diseases Annual Meeting - October 20 at 12:45 PM logoAllergan (AGN) Announces Early HSR Act Termination in Proposed Merger with Tobira - October 19 at 7:13 PM logoFTC Grants Early Termination Of HSR Waiting Period For Allergan-Tobira Deal - October 19 at 10:50 AM logoAllergan (AGN) Brings Juvederm Voluma XC to U.S. Market - October 19 at 10:50 AM logoControversy Over Allergan's 500% Premium for Tobira Looks Overdone - October 12 at 7:35 PM logoTobira Therapeutics Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting - October 3 at 11:25 AM logo6 Best Performing Drug Stocks of September - October 3 at 11:25 AM logoBotox-maker Allergan just struck another billion-dollar deal - October 3 at 11:25 AM



Tobira Therapeutics (TBRA) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff